Kansas court pre­lim­i­nar­i­ly ap­proves Vi­a­tris' $264M EpiPen set­tle­ment

A fed­er­al court has signed off on a set­tle­ment that will see Vi­a­tris pay $264 mil­lion to re­solve claims that it con­spired with Pfiz­er to “mo­nop­o­lize the mar­ket” for life-sav­ing EpiPens.

Kansas Judge Daniel Crab­tree pre­lim­i­nar­i­ly agreed to the set­tle­ment on Fri­day, paving the way for a fi­nal ap­proval that won’t come un­til at least the sec­ond half of the year. A fair­ness hear­ing will take place on Ju­ly 6, ac­cord­ing to court doc­u­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.